Abstract
Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Current Vascular Pharmacology
Title:Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs
Volume: 14 Issue: 2
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros and Asterios Karagiannis
Affiliation:
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Abstract: Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios and Karagiannis Asterios, Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/157016111402160208150816
DOI https://dx.doi.org/10.2174/157016111402160208150816 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Feature Extraction from ECG Signals and Classification/ Detection for Ventricular Arrhythmias
Recent Advances in Computer Science and Communications Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Current Pharmaceutical Design Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cyanosis Due to Methemoglobinemia Induced by Topical Anesthesia in a Premature Infant
Current Drug Therapy Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Preface
Current Nutrition & Food Science Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Early, Intensive and Long-term Statin Therapy in Acute Coronary Syndrome: Focus on Anti-inflammatory Mechanisms
Vascular Disease Prevention (Discontinued) Pulmonary Valve Endocarditis: A Case Report
Infectious Disorders - Drug Targets Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology Synthesis of Cyclodextrin-based Adsorbents and its Application for Organic Pollutant Removal from Water
Current Organic Chemistry Editorial [Hot Topic: Anti-Platelet Therapy (Guest Editor: Susan S. Smyth)]
Current Drug Targets Nutraceuticals: Beyond the Diet Before the Drugs
Current Bioactive Compounds Multicomponent Reactions for the Synthesis of Bioactive Compounds: A Review
Current Organic Synthesis